✨ Free AI Report
Reviva Pharmaceuticals Holdings, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Reviva Pharmaceuticals Holdings, Inc.
Company Research

Reviva Pharmaceuticals Holdings, Inc.: Business Overview, Financials & Competitive Analysis

Reviva Pharmaceuticals is a late-stage pharmaceutical company developing therapies to address unmet medical needs in central nervous system (CNS), inflammatory and cardiometabolic diseases. The company's lead candidat...

Analyst-debate audio for Reviva Pharmaceuticals Holdings, Inc.

AskCyborg analysts argue the bull and bear cases for Reviva Pharmaceuticals Holdings, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
4/ 10Challenged

Cyborg Score thesis

Preclinical-stage asset in critical regulatory pathway facing near-term financing challenges and delisting...

Read the full analyst-debate transcript →
Industry Neurology Drugs
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Reviva Pharmaceuticals Holdings, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Reviva Pharmaceuticals Holdings, Inc. Overview

Pro stress-test →

Reviva Pharmaceuticals is a late-stage pharmaceutical company developing therapies to address unmet medical needs in central nervous system (CNS), inflammatory and cardiometabolic diseases. The company's lead candidate is brilaroxazine, a serotonin-dopamine and neuroinflammatory signaling modulator in development for schizophrenia treatment.

Strategic Profile

Pro stress-test →

Reviva filed a composition-of-matter provisional patent application for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through 2046. Patient enrollment in the RECOVER-2 Phase 3 trial is expected in Q3 2026, with FDA feedback on the new brilaroxazine form expected in mid-2026.

Competitive Landscape

Pro stress-test →

Reviva competes in the antipsychotic/schizophrenia treatment market against established players with approved therapies. Brilaroxazine has demonstrated broad-spectrum efficacy across symptom domains in 790 trial subjects and a generally well-tolerated safety profile in over 900 subjects. Competition comes from both legacy antipsychotics and newer atypical agents.

Industry Context

Reviva Pharmaceuticals Holdings, Inc. operates in Neurology Drugs.

Key facts

Founded: 2011 · Headquarters: Cupertino, US · Employees: Unknown · Revenue: $0M (pre-commercial) · Market cap: N/A

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Reviva Pharmaceuticals Holdings, Inc..

  • FDA recommended a second Phase 3 clinical trial for brilaroxazine to generate additional efficacy data and expand the safety dataset.
  • New brilaroxazine formulation targets patent extension and commercial exclusivity, with FDA feedback expected mid-2026.
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • May 2026Stock delisted from NASDAQ and moved to OTCQB Venture Market
  • May 2026Reported Q1 2026 financial results with reduced operating expenses and disclosed FDA feedback timeline
  • +2 moreTrack every material event for Reviva Pharmaceuticals Holdings, Inc. as it happens. Explore monitoring →
Get alerted when Reviva Pharmaceuticals Holdings, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Abilify (aripiprazole)Widely-used atypical antipsychotic for schizophrenia→Risperdal (risperidone)Established atypical antipsychotic→Latuda (lurasidone)Modern antipsychotic with favorable metabolic profile→

Compare Reviva Pharmaceuticals Holdings, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Reviva Pharmaceuticals Holdings, Inc. operates in Neurology Drugs. See how the rest of the sector scores on the Cyborg framework.

Browse Neurology Drugs research →
NEW · MCP server

Ask your AI assistant about Reviva Pharmaceuticals Holdings, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Reviva Pharmaceuticals Holdings, Inc. and its top competitor on Cyborg Score”
“What did Reviva Pharmaceuticals Holdings, Inc. do this quarter?”
“Is Reviva Pharmaceuticals Holdings, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Reviva Pharmaceuticals Holdings, Inc. do?+
Reviva Pharmaceuticals is a late-stage pharmaceutical company developing therapies to address unmet medical needs in central nervous system (CNS), inflammatory and cardiometabolic diseases. The company's lead candidat...
What is Reviva Pharmaceuticals Holdings, Inc.'s Cyborg Score?+
Reviva Pharmaceuticals Holdings, Inc. has a Cyborg Score of 4/10 (Challenged). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Reviva Pharmaceuticals Holdings, Inc.'s main competitors?+
Named competitors include Abilify (aripiprazole), Risperdal (risperidone), Latuda (lurasidone). The full competitive landscape is in the AskCyborg report.
How can I get the full Reviva Pharmaceuticals Holdings, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Reviva Pharmaceuticals Holdings, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Reviva Pharmaceuticals Holdings, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.